Spark, Pfizer pass another milestone with impressive results treating hemophilia B
Spark and its partners at Pfizer have now shown that a group of 10 men treated with their gene therapy for hemophilia B can lead normal lives for about a year with no evidence of the life-threatening symptoms that plagued them. And they’re betting that it can last a lifetime.
Their new study published in the New England Journal of Medicine continues to underscore the considerable promise of gene therapy in hemophilia. By introducing a corrective gene, patients are able to make clotting factor in a normal range. All but one no longer need clotting factor. And the sole patient doesn’t need nearly as much of it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.